Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sunshine Biopharma (SBFM) over the last 10 years, with Q3 2025 value amounting to $8040.0.

  • Sunshine Biopharma's Capital Expenditures fell 9844.49% to $8040.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $278130.0, marking a year-over-year decrease of 7627.06%. This contributed to the annual value of $1.7 million for FY2024, which is 191463.2% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Capital Expenditures is $8040.0, which was down 9844.49% from $160000.0 recorded in Q2 2025.
  • Sunshine Biopharma's Capital Expenditures' 5-year high stood at $974513.0 during Q2 2024, with a 5-year trough of -$382363.0 in Q4 2023.
  • Over the past 4 years, Sunshine Biopharma's median Capital Expenditures value was $82768.5 (recorded in 2024), while the average stood at $165383.8.
  • Per our database at Business Quant, Sunshine Biopharma's Capital Expenditures crashed by 29711.26% in 2023 and then skyrocketed by 526646.25% in 2024.
  • Sunshine Biopharma's Capital Expenditures (Quarter) stood at $193982.0 in 2022, then crashed by 297.11% to -$382363.0 in 2023, then skyrocketed by 126.83% to $102600.0 in 2024, then tumbled by 92.16% to $8040.0 in 2025.
  • Its last three reported values are $8040.0 in Q3 2025, $160000.0 for Q2 2025, and $7490.0 during Q1 2025.